ERBB2 and gastric cancer: In a phase I/II study analysis, first-line treatment with LM-302 plus toripalimab (an anti-PD-1 antibody) for advanced HER2-negative GC/GEJC or EAC demonstrated promising efficacy and a manageable safety profile (NCT05188664, NCT05934331) [69].